Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone

Wang, Yujia; Wu, Guoyu; Li, Ru; Luo, Yingzhe; Huang, Xingmei; He, Lifang; Zhong, Huihui; Xiong, Shuping

doi:10.3389/fpubh.2021.677862

Cited by 9 publications

(7 citation statements)

References 38 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is a malignant tumor with high morbidity and mortality rates in the world today. 1 At present, with the increasing environmental pollution, the incidence of lung cancer is increasing year by year. 2 Surgical intervention is the preferred treatment for most patients at present, but anesthesia and surgical trauma often cause stress responses in patients.…”

Section: Introductionmentioning

confidence: 99%

Dexmedetomidine Can Reduce the Level of Oxidative Stress and Serum miR-10a in Patients with Lung Cancer after Surgery

Zhou¹,

Xia

Zhang³

2022

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Objective Lung cancer is a primary cause of cancer death. This study assessed the action of dexmedetomidine (DEX) on oxidative stress (OS) and microRNA 10a (miR-10a) in patients with lung cancer. Methods Patients were given 1 µg/kg DEX before anesthesia and control patients were given saline. The duration of intraoperative one-lung ventilation (OLV) and fluid intake were determined, and mean arterial pressure, heart rate and bispectral index were observed at the time of before anesthesia (T0), immediately after endotracheal intubation (T1), 1 hour after OLV (T2), and 10 minutes before the end of surgery (T3). The expressions and correlations of miR-10a, inflammation and OS levels in the serum were analyzed. The effects of DEX intervention and miR-10a level on pulmonary complications were analyzed. Results Patients with DEX intervention had lower levels of inflammation and OS during perioperative period than the controls. DEX intervention reduced miR-10a levels in patients during perioperative period. miR-10a in serum of patients with DEX intervention after surgery was positively-correlated with the concentrations of malondialdehyde, and inflammatory factors, while negatively-correlated with superoxide dismutase. The total incidence of postoperative pulmonary complications after DEX intervention was lowered. Patients with high miR-10a expression had a higher cumulative incidence of pulmonary complications than those with low miR-10a expression. Conclusion DEX can reduce postoperative OS and plasma miR-10a level in patients with lung cancer, and high expression of miR-10a predicts a high incidence of postoperative pulmonary complications.

show abstract

Section: Introductionmentioning

confidence: 99%

Dexmedetomidine Can Reduce the Level of Oxidative Stress and Serum miR-10a in Patients with Lung Cancer after Surgery

Zhou¹,

Xia

Zhang³

2022

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…After radiotherapy, patients with mild symptoms will experience fatigue, loss of appetite, and emotional uncertainty; some patients who have received radiotherapy for a long period will experience skin damage, esophageal damage, and lung damage, and in severe cases, they will experience radiation pneumonitis, radiation esophagitis, and bone marrow suppression, etc. ( 65 ). Incorporating Chinese medicine as an adjunct to radiotherapy can effectively mitigate the toxic side effects experienced by patients following radiotherapy.…”

Section: Treatment Of Lung Adenocarcinoma With the Combination Of Tra...mentioning

confidence: 99%

Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine

Jiang,

2024

Front. Med.

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) overwhelmingly represents the predominant histological subtype of lung cancer, with lung adenocarcinoma emerging as the most prevalent form. Conventional Western medical treatments encompass a spectrum of modalities, including surgical interventions, cytotoxic chemotherapy, radiotherapy, targeted pharmacotherapy, and immunotherapy. In contrast, Traditional Chinese Medicine (TCM) methodologies encompass traditional Chinese medicine treatments, acupuncture therapies, and tuina treatments. While conventional Western medicine has made remarkable strides in the treatment of lung cancer, it is important to acknowledge the limitations inherent in singular treatment approaches. Consequently, the quest for a more comprehensive and integrative therapeutic paradigm becomes imperative. A deficiency of evaluation criteria specific to lung adenocarcinoma treatment in the realm of TCM represents an outstanding challenge in need of resolution. Nonetheless, in the backdrop of the continuous evolution of lung adenocarcinoma treatment modalities, the amalgamation of Chinese and Western medical approaches for treating this condition has exhibited a promising trajectory. It not only contributes to mitigating toxicity and augmenting efficacy but also serves to reduce a spectrum of postoperative complications, thereby enhancing the quality of patients’ survival and extending life expectancy. This article furnishes a comprehensive survey of the research advancements in the integration of Chinese and Western medical approaches for treating lung adenocarcinoma. It elucidates the merits and demerits of individual and combined therapeutic strategies, surmounts current limitations, underscores the virtues of amalgamating Chinese and Western medical paradigms, and offers a more holistic, integrated, and efficacious treatment blueprint.

show abstract

“…The incidence of grade 3-4 serious side effects, such as rash, diarrhea, liver damage, oral ulcers, and paronychia, was reduced by 15.19% (26.67% vs. 11.48%). Chinese medicine combined with EGFR-TKIs has a tendency to enhance efficacy, prolong survival and reduce drug side effects (Wang et al, 2021b).…”

Section: Clinical Studiesmentioning

confidence: 99%

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

Song

Cao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic driver in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of lung cancer, especially in the first-line treatment of advanced NSCLC, and EGFR-TKIs monotherapy has achieved better efficacy and tolerability compared with standard chemotherapy. However, acquired resistance to EGFR-TKIs and associated adverse events pose a significant obstacle to targeted lung cancer therapy. Therefore, there is an urgent need to seek effective interventions to overcome these limitations. Natural medicines have shown potential therapeutic advantages in reversing acquired resistance to EGFR-TKIs and reducing adverse events, bringing new options and directions for EGFR-TKIs combination therapy. In this paper, we systematically demonstrated the resistance mechanism of EGFR-TKIs, the clinical strategy of each generation of EGFR-TKIs in the synergistic treatment of NSCLC, the treatment-related adverse events of EGFR-TKIs, and the potential role of traditional Chinese medicine in overcoming the resistance and adverse reactions of EGFR-TKIs. Herbs and active compounds have the potential to act synergistically through multiple pathways and multiple mechanisms of overall regulation, combined with targeted therapy, and are expected to be an innovative model for NSCLC treatment.

show abstract

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone

Cited by 9 publications

References 38 publications

Dexmedetomidine Can Reduce the Level of Oxidative Stress and Serum miR-10a in Patients with Lung Cancer after Surgery

Dexmedetomidine Can Reduce the Level of Oxidative Stress and Serum miR-10a in Patients with Lung Cancer after Surgery

Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine

Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice

Contact Info

Product

Resources

About